Genomic and transcriptomic correlates of Richter transformation in chronic lymphocytic leukemia

被引:64
作者
Klintman, Jenny [1 ,2 ,3 ]
Appleby, Niamh [1 ,2 ,4 ]
Stamatopoulos, Basile [1 ,5 ]
Ridout, Katie [1 ,2 ]
Eyre, Toby A. [4 ]
Robbe, Pauline [1 ,2 ]
Pascua, Laura Lopez [1 ,2 ]
Knight, Samantha J. L. [6 ,7 ]
Dreau, Helene [1 ,2 ]
Cabes, Maite [4 ]
Popitsch, Niko [6 ,7 ,8 ]
Ehinger, Mats [9 ]
Martin-Subero, Jose I. [10 ,11 ]
Campo, Elias [10 ]
Mansson, Robert [12 ,13 ]
Rossi, Davide [14 ]
Taylor, Jenny C. [6 ,7 ]
Vavoulis, Dimitrios V. [1 ,2 ,6 ,7 ]
Schuh, Anna [1 ,2 ,4 ,6 ]
机构
[1] Univ Oxford, Dept Oncol, Mol Diagnost Ctr, Oxford, England
[2] Univ Oxford, Dept Oncol, Oxford, England
[3] Lund Univ, Skane Univ Hosp, Dept Translat Med, Lund, Sweden
[4] Oxford Univ Hosp Natl Hlth Serv NHS Trust, Dept Hematol, Oxford, England
[5] Univ Libre Bruxelles ULB, Inst Jules Bordet, Lab Clin Cell Therapy, Brussels, Belgium
[6] Univ Oxford, Natl Inst Hlth Res NIHR Oxford Biomed Res Ctr, Oxford, England
[7] Univ Oxford, Wellcome Ctr Human Genet, Oxford, England
[8] Childrens Canc Res Inst CCRI, Vienna, Austria
[9] Lund Univ, Skane Univ Hosp, Dept Clin Sci, Pathol, Lund, Sweden
[10] Inst Invest Biomed August Pi Sunyer IDIBAPS, Barcelona, Spain
[11] Inst Catalana Recerca & Estudis Avancats ICREA, Barcelona, Spain
[12] Karolinska Inst, Ctr Hematol & Regenerat Med Huddinge, Stockholm, Sweden
[13] Karolinska Univ Hosp, Hematol Ctr, Stockholm, Sweden
[14] Inst Oncol Res IOR, Bellinzona, Switzerland
基金
英国惠康基金;
关键词
RNA-SEQ DATA; RECURRENT MUTATIONS; CELL-GROWTH; IBRUTINIB; RESISTANCE; PROGRESSION; OFATUMUMAB; SUPPRESSOR; EVOLUTION; OUTCOMES;
D O I
10.1182/blood.2020005650
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The transformation of chronic lymphocytic leukemia (CLL) to high-grade B-cell lymphoma is known as Richter syndrome (RS), a rare event with dismal prognosis. In this study, we conducted whole-genome sequencing (WGS) of paired circulating CLL (PB-CLL) and RS biopsies (tissue-RS) from 17 patients recruited into a clinical trial (CHOP-0). We found that tissue-RS was enriched for mutations in poor-risk CLL drivers and genes in the DNA damage response (DDR) pathway. In addition, we identified genomic aberrations not previously implicated in RS, including the protein tyrosine phosphatase receptor (PTPRD) and tumor necrosis factor receptor-associated factor 3 (TRAF3). In the noncoding genome, we discovered activation-induced cytidine deaminase related and unrelated kataegis in tissue RS affecting regulatory regions of key immune regulatory genes. These include BTG2, CXCR4, NFATC1, PAX5, NOTCH 1, SLC44A5, FCRL3, SELL, TNIP2, and TRIM13. Furthermore, differences between the global mutation signatures of pairs of PB-CLL and tissue-RS samples implicate DDR as the dominant mechanism driving transformation. Pathway-based clonal deconvolution analysis showed that genes in the MAPK and DDR pathways demonstrate high clonal-expansion probability. Direct comparison of nodal-CLL and tissue-RS pairs from an independent cohort confirmed differential expression of the same pathways by RNA expression profiling. Our integrated analysis of WGS and RNA expression data significantly extends previous targeted approaches, which were limited by the lack of germline samples, and it facilitates the identification of novel genomic correlates implicated in RS transformation, which could be targeted therapeutically. Our results inform the future selection of investigative agents for a UK clinical platform study.
引用
收藏
页码:2800 / 2816
页数:17
相关论文
共 76 条
  • [11] Ibrutinib versus Ofatumumab in Previously Treated Chronic Lymphoid Leukemia
    Byrd, J. C.
    Brown, J. R.
    O'Brien, S.
    Barrientos, J. C.
    Kay, N. E.
    Reddy, N. M.
    Coutre, S.
    Tam, C. S.
    Mulligan, S. P.
    Jaeger, U.
    Devereux, S.
    Barr, P. M.
    Furman, R. R.
    Kipps, T. J.
    Cymbalista, F.
    Pocock, C.
    Thornton, P.
    Caligaris-Cappio, F.
    Robak, T.
    Delgado, J.
    Schuster, S. J.
    Montillo, M.
    Schuh, A.
    de Vos, S.
    Gill, D.
    Bloor, A.
    Dearden, C.
    Moreno, C.
    Jones, J. J.
    Chu, A. D.
    Fardis, M.
    McGreivy, J.
    Clow, F.
    James, D. F.
    Hillmen, P.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2014, 371 (03) : 213 - 223
  • [12] The WHIM-like CXCR4S338X somatic mutation activates AKT and ERK, and promotes resistance to ibrutinib and other agents used in the treatment of Waldenstrom's Macroglobulinemia
    Cao, Y.
    Hunter, Z. R.
    Liu, X.
    Xu, L.
    Yang, G.
    Chen, J.
    Patterson, C. J.
    Tsakmaklis, N.
    Kanan, S.
    Rodig, S.
    Castillo, J. J.
    Treon, S. P.
    [J]. LEUKEMIA, 2015, 29 (01) : 169 - 176
  • [13] Two main genetic pathways lead to the transformation of chronic lymphocytic leukemia to Richter syndrome
    Chigrinova, Ekaterina
    Rinaldi, Andrea
    Kwee, Ivo
    Rossi, Davide
    Rancoita, Paola M. V.
    Strefford, Jonathan C.
    Oscier, David
    Stamatopoulos, Kostas
    Papadaki, Theodora
    Berger, Francoise
    Young, Ken H.
    Murray, Fiona
    Rosenquist, Richard
    Greiner, Timothy C.
    Chan, Wing C.
    Orlandi, Ester M.
    Lucioni, Marco
    Marasca, Roberto
    Inghirami, Giorgio
    Ladetto, Marco
    Forconi, Francesco
    Cogliatti, Sergio
    Votavova, Hana
    Swerdlow, Steven H.
    Stilgenbauer, Stephan
    Piris, Miguel A.
    Matolcsy, Andras
    Spagnolo, Dominic
    Nikitin, Eugene
    Zamo, Alberto
    Gattei, Valter
    Bhagat, Govind
    Ott, German
    Zucca, Emanuele
    Gaidano, Gianluca
    Bertoni, Francesco
    [J]. BLOOD, 2013, 122 (15) : 2673 - 2682
  • [14] The MEK1/2 inhibitor, MEKi-1, induces cell death in chronic lymphocytic leukemia cells under conditions that mimic the tumor microenvironment and is synergistic with fludarabine
    Crassini, Kyle
    Stevenson, William S.
    Mulligan, Stephen P.
    Best, O. Giles
    [J]. LEUKEMIA & LYMPHOMA, 2015, 56 (12) : 3407 - 3417
  • [15] The molecular functions of Shp2 in the Ras/Mitogen-activated protein kinase (ERK1/2) pathway
    Dance, Marie
    Montagner, Alexandra
    Salles, Jean-Pierre
    Yart, Armelle
    Raynal, Patrick
    [J]. CELLULAR SIGNALLING, 2008, 20 (03) : 453 - 459
  • [16] Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
    Davis, R. Eric
    Ngo, Vu N.
    Lenz, Georg
    Tolar, Pavel
    Young, Ryan M.
    Romesser, Paul B.
    Kohlhammer, Holger
    Lamy, Laurence
    Zhao, Hong
    Yang, Yandan
    Xu, Weihong
    Shaffer, Arthur L.
    Wright, George
    Xiao, Wenming
    Powell, John
    Jiang, Jian-Kang
    Thomas, Craig J.
    Rosenwald, Andreas
    Ott, German
    Muller-Hermelink, Hans Konrad
    Gascoyne, Randy D.
    Connors, Joseph M.
    Johnson, Nathalie A.
    Rimsza, Lisa M.
    Campo, Elias
    Jaffe, Elaine S.
    Wilson, Wyndham H.
    Delabie, Jan
    Smeland, Erlend B.
    Fisher, Richard I.
    Braziel, Rita M.
    Tubbs, Raymond R.
    Cook, J. R.
    Weisenburger, Dennis D.
    Chan, Wing C.
    Pierce, Susan K.
    Staudt, Louis M.
    [J]. NATURE, 2010, 463 (7277) : 88 - U97
  • [17] MGA, a suppressor of MYC, is recurrently inactivated in high risk chronic lymphocytic leukemia
    De Paoli, Lorenzo
    Cerri, Michaela
    Monti, Sara
    Rasi, Silvia
    Spina, Valeria
    Bruscaggin, Alessio
    Greco, Mariangela
    Ciardullo, Carmela
    Fama, Rosella
    Cresta, Stefania
    Maffei, Rossana
    Ladetto, Marco
    Martini, Maurizio
    Laurenti, Luca
    Forconi, Francesco
    Marasca, Roberto
    Larocca, Luigi M.
    Bertoni, Francesco
    Gaidano, Gianluca
    Rossi, Davide
    [J]. LEUKEMIA & LYMPHOMA, 2013, 54 (05) : 1087 - 1090
  • [18] Genomic alterations in high-risk chronic lymphocytic leukemia frequently affect cell cycle key regulators and NOTCH1-regulated transcription
    Edelmann, Jennifer
    Holzmann, Karlheinz
    Tausch, Eugen
    Saunderson, Emily A.
    Jebaraj, Billy M. C.
    Steinbrecher, Daniela
    Dolnik, Anna
    Blaette, Tamara J.
    Landau, Dan A.
    Saub, Jenny
    Estenfelder, Sven
    Ibach, Stefan
    Cymbalista, Florence
    Leblond, Veronique
    Delmer, Alain
    Bahlo, Jasmin
    Robrecht, Sandra
    Fischer, Kirsten
    Goede, Valentin
    Bullinger, Lars
    Wu, Catherine J.
    Mertens, Daniel
    Ficz, Gabriella
    Gribben, John G.
    Hallek, Michael
    Doehner, Hartmut
    Stilgenbauer, Stephan
    [J]. HAEMATOLOGICA, 2020, 105 (05) : 1379 - 1390
  • [19] NCRI phase II study of CHOP in combination with ofatumumab in induction and maintenance in newly diagnosed Richter syndrome
    Eyre, Toby A.
    Clifford, Ruth
    Bloor, Adrian
    Boyle, Lucy
    Roberts, Corran
    Cabes, Maite
    Collins, Graham P.
    Devereux, Stephen
    Follows, George
    Fox, Christopher P.
    Gribben, John
    Hillmen, Peter
    Hatton, Chris S.
    Littlewood, Tim J.
    McCarthy, Helen
    Murray, Jim
    Pettitt, Andrew R.
    Soilleux, Elizabeth
    Stamatopoulos, Basile
    Love, Sharon B.
    Wotherspoon, Andrew
    Schuh, Anna
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2016, 175 (01) : 43 - 54
  • [20] Genetic lesions associated with chronic lymphocytic leukemia transformation to Richter syndrome
    Fabbri, Giulia
    Khiabanian, Hossein
    Holmes, Antony B.
    Wang, Jiguang
    Messina, Monica
    Mullighan, Charles G.
    Pasqualucci, Laura
    Rabadan, Raul
    Dalla-Favera, Riccardo
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 2013, 210 (11) : 2273 - 2288